Loading ......
Ariola Virus is a member of the Orthopoxvirus genus in the Poxvirudae family, and has caused the highly infectious disease smallpox. The average incubation period of patients is 12 days (7-17 days), and typical symptoms include high fever, fatigue, headache, rapid heartbeat, back pain, and systemic rash. The rash initially appears as a light red block and is densely distributed on the face, arms, and legs. The lesion suppurates 2-3 days later, scabs begin to form in the second week, and gradually forms scabies and peels off in the following 3-4 weeks, leaving scars after recovery. The patient's facial scars are the origin of the disease name "smallpox". Tools such as anti smallpox virus, Anti-Ariola virus Variola virus Protein J5 Polyclonal antibody, and recombinant variola virus a27l protein have become key assets, which help advance vaccine research and prepare strategies for potential smallpox recurrence or biological threats.
Figure 1. Structure of Ariola Virus. (Smith, Geoffrey L,et al, 2002)
Smallpox may have initially been a relatively harmless poxvirus in livestock, but it gradually evolved and adapted to form smallpox, a human disease. And in the future, people gradually discovered accidental cases similar to cowpox infecting humans. The deadly adaptation process of smallpox may have occurred after humans entered the agricultural era, where people began to domesticate new animals and live with them, often in the same house. Smallpox may also have originated from contact between humans and wild animals, just like the few people in Central Africa today who were infected with monkeypox. The common virus is Ariola Virus, which is a type of smallpox and also a type of poxvirus. In addition to large smallpox, smallpox is also divided into medium smallpox and small smallpox. Large smallpox, medium smallpox and small smallpox have exactly the same disease and the same mode of infection. The difference between them is that about 25% of patients infected with large smallpox will die, the mortality rate of medium smallpox is about 12%, and only 1% of those infected with small smallpox are life-threatening.
Ariola Virus employs a multistep process to infect host cells:
During the first week after infection, the virus only moves quietly within the patient's body. The patient will not have any symptoms, and even if he suspects that he may have been infected, he cannot be certain. Around the ninth day, the first signs of illness began to appear: headache, fever, nausea, back pain, sometimes accompanied by spasms or neurological disorders. During this incubation period, some patients may also have nightmares that last for three to four days. Patients with fair skin often have scattered deep red spots on their faces, sometimes spreading throughout their entire body. At the end of the incubation period, the patient's high fever subsided and their condition temporarily improved. It was at this time that the Ariola Virus began to produce its characteristic rash on the patient's body, declaring its existence. Usually, these flat light red acne spots first appear on the patient's face, then quickly spread to the arms, chest, back, and finally reach the legs.
The Ariola Virus reproduces rapidly and spreads through the air at an astonishing speed. People carrying the virus are most contagious within one week of infection because their saliva contains the highest amount of Ariola Virus. However, smallpox may still be transmitted to others through the patient until the scar is removed. There are different varieties of Ariola Virus, which can cause varying degrees of infection to humans. Most smallpox patients will recover, and death often occurs within 1 or 2 weeks after onset, with a mortality rate of about 30%.
Understanding the molecular composition of VARV is crucial for developing vaccines and recent antiviral drugs. The key targets include viral proteins involved in replication, morphogenesis, and immune evasion.
| Diagnosis | Details |
| Antiviral drug targets | VP37 protein: The viral VP37 protein is a key target for antiviral therapy (encoded by the F13L gene in VACV). It is crucial for the production of extracellular envelope virus particles (EEVs). DNA polymerase: Viral DNA polymerase (protein complex encoded by E9L, D5R, and D4R genes) is a classic target for antiviral drug development. |
| Vaccine antigen targets | Antibodies are crucial for protection, primarily targeting viral membrane proteins in MV and EV forms. The key targets for neutralizing antibodies include: A27L (MV membrane): Participate in cell attachment and fusion. B5R (EV membrane): a key target of antibodies that neutralize extracellular viruses and limit their transmission. Antibodies against L1R and A33R (another EV protein) are also important for protection. Internal and non structural proteins: T cells, especially CD8+cytotoxic T lymphocytes (CTLs), are crucial for clearing infected cells. They recognize peptides from both structural and non structural viral proteins. One key antigen is the E3L protein, which is a highly conserved immediate early protein in orthopoxvirus. |
The Ariola Virus was a major scourge on humanity, ultimately defeated through a massive global vaccination campaign. Its eradication proves the determination of scientific cooperation and public health. The study of the complex biology of VARV - from its vast DNA genome and cytoplasmic replication cycle to its complex mechanism of evading host immunity - provides profound insights into virology and immunology. Although the virus no longer spreads in nature, the molecular knowledge gained, especially key viral targets such as VP37 protein (for Tigavirus), DNA polymerase (for Brincidofovir), and immunogenic proteins such as E3L and B5R (for vaccines), remains crucial. These knowledge support the development of new strategies, not only for the prevention of smallpox, but also for other positive poxvirus threats such as monkeypox. The continuous research on the genetics and pathogenesis of VARV ensures that the world remains prepared for this conquered but still powerful pathogen.
Reference
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| Ariola virus Variola virus Protein J5 | DPAB-DC4867 | Anti-Ariola virus Variola virus Protein J5 Polyclonal antibody | Rabbit | IgG | WB, ELISA | Inquiry |
| DPAB-DC4868 | Anti-Ariola virus Variola virus Protein J5 Polyclonal antibody | Rabbit | IgG | WB, ELISA | Inquiry | |
| DPAB-DC4869 | Anti-Ariola virus Variola virus Protein J5 Polyclonal antibody | Rabbit | IgG | WB, ELISA | Inquiry |
| Target | Cat. No. | Product Name | Host | |
| Variola virus A27L | DAG-WT1092 | Recombinant Variola Virus A27L Protein [His] | HEK293 cells | Inquiry |
| Variola virus L1 | DAG-WT1093 | Recombinant Variola Virus L1 Protein [His] | HEK293 cells | Inquiry |
| DAG2609 | Recombinant Variola virus Variola CRMB (a.a. 23-349) [His] | Mouse | Inquiry |
Loading ......